IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion

Rhea-AI Summary

IGC Pharma (NYSE American: IGC) added Kerwin Medical Center in Dallas as a clinical site to its Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer's disease on April 22, 2026. The company reported approximately 80% enrollment and says the new site brings behavioral neurology expertise to support final recruitment and data quality.

The site's Principal Investigator is Dr. Alka Khera, M.D., and Kerwin Medical Center is part of the Pinnacle Network, bringing community-based research experience intended to aid patient access and retention as the trial advances toward enrollment completion.

Positive

• Enrollment ~80% of Phase 2 CALMA trial completed
• Added Kerwin site with behavioral neurology PI Dr. Alka Khera in Dallas
• Expanded patient access via Pinnacle Network community site

Negative

• None.

News Market Reaction – IGC

+10.17% 1.5x vol

19 alerts

+10.17% Session close to close

+16.8% Peak in 5 hr 30 min

$35.02M Market Cap

1.5x Rel. Volume

In the Apr 22 session, IGC gained 10.17%, reflecting a significant positive market reaction. Argus tracked a peak move of +16.8% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. Trading volume was above average at 1.5x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +10.2% in the session following this news. A strong positive reaction aligns with p...

Analysis

The stock surged +10.2% in the session following this news. A strong positive reaction aligns with prior CALMA updates that often produced modest gains of up to 4.41%. This site addition continues the pattern of expanding a now ~80%-enrolled Phase 2 network. Investors have an effective S-3/A resale registration over 978,235 shares to monitor, alongside limited cash highlighted in recent filings, as they assess how durable enthusiasm for clinical progress might be.

Key Figures

CALMA enrollment: approximately 80%

1 metrics

CALMA enrollment approximately 80% Phase 2 CALMA trial enrollment status

Previous Clinical trial Reports

5 past events · Latest: Apr 14 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 14	CALMA enrollment update	Positive	+4.4%	Reported ~80% enrollment and entry into final recruitment phase for CALMA.
Apr 07	New CALMA site	Positive	+0.9%	Added Tandem Clinical Research site with enrollment over 70% complete.
Feb 23	New CALMA site	Positive	+2.2%	Added Visionary Investigators Network; about 70% of enrollment completed.
Feb 17	Patent and CALMA status	Positive	+0.0%	Secured composition protection for IGC-AD1 as CALMA neared 70% enrollment.
Feb 09	CALMA expansion	Positive	+1.2%	Expanded CALMA into Colombia; network to 23 sites and ~70% enrollment.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Clinical trial updates for CALMA have generally coincided with small positive price moves, with one flat reaction despite positive news.

Recent Company History

Over recent months, IGC has repeatedly highlighted progress in its Phase 2 CALMA trial for IGC-AD1, including expansion into Colombia with 23 active sites across 26 locations and multiple site additions as enrollment moved from ≈70% to ≈80%. These updates, plus composition protection for IGC-AD1, have typically produced modest gains of up to 4.41%. Today’s addition of Kerwin Medical Center continues this pattern of network expansion as CALMA nears full enrollment.

Key Terms

behavioral neurology, phase 2, alzheimer's disease, mild cognitive impairment, +2 more

6 terms

behavioral neurology medical

"The site's Principal Investigator is Dr. Alka Khera, M.D., a behavioral neurologist..."

Behavioral neurology studies how the brain controls thinking, memory, language and social behavior, and focuses on diagnosing and treating conditions that change those abilities. It matters to investors because advances in tests, treatments, devices or care approaches can create new markets or lower costs—like fixing an operating system so applications run properly—and those changes can materially affect healthcare companies’ revenues and valuations.

phase 2 medical

"as a clinical site in the Company's Phase 2 CALMA trial evaluating IGC-AD1..."

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

alzheimer's disease medical

"developing therapeutics for Alzheimer's disease, today announced the addition..."

A progressive brain disorder that slowly erodes memory, thinking and the ability to carry out daily tasks as nerve cells are damaged and lost; symptoms typically worsen over years and can lead to severe impairment. Investors care because it drives a large, growing market for diagnostics, treatments and care services, but also carries high scientific, regulatory and commercial risk—similar to developing a complex new product that must pass difficult safety tests before it can reach patients.

mild cognitive impairment medical

"experience in Alzheimer's disease, mild cognitive impairment, frontotemporal dementia..."

Mild cognitive impairment (MCI) is a medical condition where a person experiences noticeable decline in memory or thinking that is greater than expected for their age but does not yet interfere significantly with daily life, like forgetting appointments more often while still managing basic tasks. For investors, MCI matters because it defines a target patient group, shapes the size and urgency of markets for diagnostics and treatments, and influences clinical trial design, regulatory pathways and potential revenue for companies developing related drugs or tests.

frontotemporal dementia medical

"mild cognitive impairment, frontotemporal dementia, and related neurodegenerative conditions."

A progressive neurological disorder that damages the brain regions controlling behavior, personality, language and movement, causing gradual changes in judgment, speech and social skills—like a control center in the head slowly losing its ability to coordinate those functions. It matters to investors because it creates demand for diagnostics, therapies and long‑term care, shapes clinical trial risk and regulatory outcomes, and can influence revenue prospects for pharmaceutical, biotech and medical services companies.

neurodegenerative medical

"and related neurodegenerative conditions.The site's Principal Investigator..."

Neurodegenerative describes diseases where nerve cells in the brain or spinal cord progressively lose function and die, causing worsening movement, memory or other mental abilities over time. For investors this matters because such conditions create large, long-term needs for therapies and caregiving; developing treatments often requires lengthy, expensive research and regulatory testing but can lead to substantial, sustained market opportunities if a therapy proves effective — like fixing the wiring in a whole neighborhood rather than a single house.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Behavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer's agitation study

POTOMAC, MD / ACCESS Newswire / April 22, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced the addition of Kerwin Medical Center in Dallas, Texas as a clinical site in the Company's Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer's disease. The Company recently reported approximately 80% enrollment in CALMA and continues to advance toward enrollment completion.

The addition comes as the CALMA trial advances through its final phase of enrollment and reflects the Company's continued focus on strengthening site quality, expanding patient access, and supporting consistent execution across its clinical network. Kerwin Medical Center brings focused experience in Alzheimer's disease, mild cognitive impairment, frontotemporal dementia, and related neurodegenerative conditions.

The site's Principal Investigator is Dr. Alka Khera, M.D., a behavioral neurologist with experience conducting Alzheimer's clinical trials. IGC Pharma believes that adding specialized behavioral neurology expertise in a major U.S. metropolitan area supports both recruitment and clinical rigor as the study progresses toward enrollment completion.

"Kerwin Medical Center adds meaningful clinical depth to our CALMA network at an important stage of the trial," said Ram Mukunda, CEO. "Dr. Khera's experience in behavioral neurology and the site's research infrastructure strengthen our ability to execute efficiently as we advance toward enrollment completion. As the trial approaches its next milestones, site quality and operational consistency remain critical to generating robust and reliable data."

Kerwin Medical Center is part of the Pinnacle Network and has experience supporting patient participation and retention in dementia-related clinical trials. The Company believes that this type of community-based engagement is particularly valuable in neurodegenerative research, where continuity of care and trust can play an important role in study execution.

More information about the CALMA study: Link

About IGC Pharma (dba IGC):

IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With a complete patent portfolio and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially, including risks related to the Company's ability to complete enrollment in its Phase 2 CALMA trial within anticipated timeframes, demonstrate safety and efficacy, the timing of data readouts, regulatory approvals, and other factors discussed in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including its most recent Annual Report on Form 10-KT. The Company undertakes no obligation to update these statements.

Contact Information:

Walter Frank / John Nesbett
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200

SOURCE: IGC Pharma, Inc.

View the original press release on ACCESS Newswire

FAQ

How far along is enrollment in IGC Pharma's CALMA Phase 2 trial (IGC) as of April 22, 2026?

Approximately 80% of enrollment is complete, according to the company. This indicates the study is in its final recruitment phase, with added sites like Kerwin Medical Center intended to help finish enrollment and improve patient retention.

What role does Kerwin Medical Center play in IGC Pharma's CALMA trial (IGC)?

Kerwin Medical Center was added as a clinical site to support recruitment and clinical rigor, according to the company. The site brings behavioral neurology expertise and community-based research experience as the trial advances toward enrollment completion.

Who is the Principal Investigator at the new CALMA trial site added by IGC Pharma (IGC)?

The Principal Investigator is Dr. Alka Khera, M.D., a behavioral neurologist, according to the company. Her experience conducting Alzheimer's clinical trials is cited as strengthening site quality and operational consistency during final enrollment.

Does the addition of Kerwin Medical Center affect patient access for IGC Pharma's CALMA trial (IGC)?

Yes, the company says the Kerwin site expands patient access and supports retention. Being part of the Pinnacle Network, the site aims to leverage community engagement to maintain continuity of care and improve study execution.

What expertise does Kerwin Medical Center contribute to IGC Pharma's CALMA study (IGC)?

Kerwin contributes focused experience in Alzheimer's, mild cognitive impairment, and frontotemporal dementia, according to the company. That behavioral neurology expertise is intended to support recruitment quality and the reliability of clinical data as the trial nears completion.

How does IGC Pharma describe the importance of site quality as CALMA enrollment finishes (IGC)?

IGC says site quality and operational consistency remain critical to generate robust, reliable data as enrollment completes. The company emphasizes specialized investigators and research infrastructure to support efficient execution in late-stage recruitment.